Contineum Therapeutics to Present at 45th Goldman Sachs Healthcare Conference

Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, is set to participate in the 45th Annual Goldman Sachs Healthcare Conference from June 10-13, 2024, in Miami. The company specializes in discovering and developing novel, oral small molecule therapies targeting biological pathways related to neuroscience, inflammation, and immunology (NI&I) conditions.

Carmine Stengone, President and Chief Executive Officer of Contineum, will be featured in a fireside chat on June 10, 2024, at 8:40 am Eastern Time. Additionally, the management team will conduct one-on-one meetings with investors during the event. A live webcast of the fireside chat will be accessible through the Investors section of Contineum's website, with a replay available after the event concludes.

About Contineum Therapeutics

Headquartered in San Diego, CA, Contineum Therapeutics (Nasdaq: CTNM) is committed to addressing high unmet medical needs by focusing on the development of oral small molecule therapies for NI&I indications. The company's strategy revolves around targeting specific biological pathways that, once modulated, could significantly alter the course of diseases.

The company's pipeline includes several internally-developed programs aimed at treating multiple NI&I disorders. One notable program is PIPE-791, an LPA1 receptor antagonist. This program recently completed a Phase 1 clinical trial involving healthy volunteers to support ongoing development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis. Another significant program is PIPE-307, a selective inhibitor of the M1 receptor. PIPE-307 is currently in a Phase 2 clinical trial for relapse-remitting multiple sclerosis, with plans for a Phase 2 trial in depression set to commence in 2024. The development of PIPE-307 is in collaboration with Johnson & Johnson Innovative Medicines.

Contineum Therapeutics is at the forefront of innovative treatments targeting critical areas in neuroscience, inflammation, and immunology, with a robust pipeline of promising therapeutic candidates.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!